Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pizalin is a fixed-dose combination of choline alfoscerate (alpha-GPC) and piracetam, developed by Primus Remedies. It is used as a cognitive enhancer to improve memory, attention, and overall brain function in patients with cognitive decline, dementia, Alzheimer's disease, or recovering from stroke or head injury. Choline alfoscerate acts as a highly bioavailable precursor to acetylcholine, increasing its levels in the brain to support memory and learning. Piracetam, a nootropic agent, enhances neuronal communication, improves membrane fluidity, and increases the activity of acetylcholine and other neurotransmitters. Together, they work synergistically to provide neuroprotection and support cognitive rehabilitation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on choline alfoscerate + piracetam.